On this page
Hereditary elliptocytosis
Most people with hereditary elliptocytosis have no symptoms, though some experience mild anaemia or jaundice. The condition is caused by changes in genes that affect the structural proteins of red blood cell membranes, and it follows an autosomal dominant inheritance pattern.
Overview
Hereditary elliptocytosis is a group of inherited disorders affecting the shape and stability of red blood cells. In affected individuals, a substantial proportion of red blood cells appear oval or elliptical when examined under a microscope, rather than the typical biconcave disc shape seen in healthy cells [PMID:12505054]. The prevalence varies considerably across different populations, with estimates suggesting the condition may affect around 1 in 2,500 people in certain populations, particularly some African and Mediterranean groups, whilst being less common in Northern European populations.
The clinical severity of hereditary elliptocytosis ranges widely. Many people with the condition remain completely asymptomatic throughout their lives and are identified only incidentally during routine blood tests. Others may experience mild to moderate haemolytic anaemia, where red blood cells break down more quickly than normal [PMID:15232403]. A smaller subset develops more severe complications, particularly in infancy. The condition belongs to a broader category of red cell membrane disorders that also includes hereditary spherocytosis and hereditary pyropoikilocytosis.
Symptoms & clinical features
The majority of individuals with hereditary elliptocytosis have no noticeable symptoms and lead entirely normal lives without requiring any medical intervention. When symptoms do occur, they typically relate to chronic haemolytic anaemia - the premature destruction of red blood cells. Affected individuals may experience mild fatigue, pallor, or reduced exercise tolerance, though these features are often subtle and do not significantly impact daily activities [PMID:19247979].
Some people develop jaundice, particularly during periods of physiological stress such as infections or pregnancy, when the rate of red blood cell breakdown temporarily increases. In these circumstances, the yellow discolouration of the skin and whites of the eyes reflects elevated bilirubin levels, a breakdown product of haemoglobin. Enlargement of the spleen is occasionally observed, as this organ works harder to remove abnormally shaped red blood cells from circulation. A small number of affected individuals, particularly those with more severe variants, may develop gallstones composed of bilirubin, typically in adulthood.
Video: Genetics 101
Affected organs
Hereditary elliptocytosis primarily affects the blood and organs involved in red blood cell processing. The abnormally shaped red blood cells are more fragile than normal and may be removed prematurely by the spleen, leading to mild splenic enlargement in some cases. The liver processes the increased bilirubin load resulting from red cell breakdown, which can lead to a slightly elevated baseline bilirubin level even in asymptomatic individuals.
In the small proportion of people who experience significant haemolytic anaemia, the bone marrow compensates by increasing red blood cell production. Over time, chronic haemolysis may contribute to the formation of pigmented gallstones in the gallbladder. The cardiovascular system is generally not directly affected, though severe anaemia - when present - may place additional demands on the heart.
Risks & severity
The clinical spectrum of hereditary elliptocytosis ranges from entirely asymptomatic to severe haemolytic anaemia requiring medical management. Research suggests that the great majority of affected individuals have either no symptoms or only mild laboratory abnormalities [PMID:12505054]. The remainder experience varying degrees of chronic haemolysis, with symptoms typically becoming apparent in childhood or early adulthood.
A rare but severe variant called hereditary pyropoikilocytosis can occur in individuals who inherit two different pathogenic variants affecting red cell membrane proteins. This presents in infancy with severe haemolytic anaemia and marked red blood cell fragmentation. Life expectancy for people with typical hereditary elliptocytosis is normal, and most affected individuals do not require ongoing medical treatment. Complications such as gallstones or episodes of more severe haemolysis during infections may occur but are generally manageable.
Genetic causes
Hereditary elliptocytosis results from pathogenic variants in genes encoding structural proteins of the red blood cell membrane skeleton. The most commonly implicated genes include SPTA1, SPTB, EPB41, and SLC4A1, which encode structural proteins of the red blood cell membrane skeleton. SPTA1 encodes spectrin alpha, a major component of the membrane cytoskeleton that provides mechanical strength and flexibility to red blood cells [PMID:15232403]. Spectrin molecules form a network beneath the cell membrane, allowing red blood cells to deform as they pass through narrow capillaries and then recover their shape.
EPB41 encodes protein 4.1, which helps anchor the spectrin network to the cell membrane and maintains the structural integrity of red blood cells. When pathogenic variants disrupt the normal function of these proteins, the membrane skeleton becomes mechanically unstable. This causes red blood cells to lose their normal disc shape and assume an elliptical form [PMID:19247979]. The degree of membrane instability varies depending on the specific variant and which protein is affected, explaining the wide range in clinical severity. In some cases, the abnormal membrane is fragile enough that red blood cells rupture prematurely in the circulation, leading to haemolytic anaemia.
- EPB41 erythrocyte membrane protein band 4.1
- SPTA1 spectrin alpha, erythrocytic 1
Inheritance pattern
Hereditary elliptocytosis follows an autosomal dominant pattern of inheritance. This means that inheriting one pathogenic variant in a causative gene is typically sufficient to cause the condition. Each child of an affected parent has a 50% chance of inheriting the variant and developing the condition. Both males and females are equally likely to be affected.
Because many people with hereditary elliptocytosis have no symptoms, family members may be unaware they carry a pathogenic variant until genetic testing is performed. Rarely, individuals inherit pathogenic variants from both parents, which can result in more severe disease. Genetic counselling can help families understand the inheritance pattern and implications for relatives, particularly when considering family planning.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
Diagnosis of hereditary elliptocytosis typically begins with a blood film examination, where laboratory scientists observe the characteristic oval or elliptical shape of red blood cells under a microscope. A complete blood count may show mild anaemia and features of haemolysis, such as an elevated reticulocyte count indicating increased red blood cell production. Additional laboratory tests might include bilirubin levels and markers of red blood cell breakdown.
Genetic testing can confirm the diagnosis by identifying pathogenic variants in causative genes such as SPTA1 or EPB41. In the NHS, genetic testing for hereditary elliptocytosis may be arranged through clinical genetics services or haematology specialists. Testing is particularly valuable when the diagnosis is uncertain, when more severe disease is present, or for family planning purposes. Referral pathways typically involve initial assessment by a haematologist, who may then refer to clinical genetics for genetic counselling and testing coordination.
Management & lifestyle
Most people with hereditary elliptocytosis require no specific treatment and can lead entirely normal lives without medical intervention. For those with symptomatic haemolytic anaemia, management focuses on monitoring blood counts and supporting the body's compensatory mechanisms. Folic acid supplementation is sometimes recommended for individuals with chronic haemolysis, as the increased red blood cell production raises folate requirements [PMID:19247979].
In severe cases with significant anaemia, removal of the spleen may be considered to reduce the rate of red blood cell destruction. This intervention is reserved for people with substantial symptoms affecting quality of life, as it carries risks including increased susceptibility to certain infections. Blood transfusions are rarely needed except during acute haemolytic crises triggered by infections or other stressors. Within the NHS, ongoing care is typically coordinated through haematology services, with access to genetic counselling available for family planning discussions and cascade testing of relatives.
UK care pathway
In the UK, hereditary elliptocytosis is managed within NHS haematology services, with genetic testing available through regional genetics laboratories. Individuals suspected of having the condition are typically referred by their GP to a haematologist for clinical assessment and blood film examination. If genetic testing is indicated, referral to clinical genetics services provides access to genetic counselling and formal testing.
The NHS Genomic Medicine Service includes red blood cell membrane disorders in relevant testing panels. Genetic counsellors can discuss inheritance patterns with families, coordinate cascade testing for at-risk relatives, and provide information about reproductive options. For most affected individuals, follow-up is minimal once the diagnosis is established, with routine monitoring reserved for those experiencing symptomatic anaemia.
Frequently asked questions
Will I need treatment if I have hereditary elliptocytosis?
Most people with hereditary elliptocytosis do not require any treatment and remain healthy throughout their lives. Treatment is only considered for the minority who experience significant anaemia or other symptoms. Your haematologist will monitor your blood counts and advise on whether any intervention is needed.
Can hereditary elliptocytosis get worse over time?
For most people, hereditary elliptocytosis remains stable throughout life. Temporary worsening of anaemia can occur during infections or pregnancy, but this typically resolves once the stressor passes. Regular monitoring helps identify any changes that might need attention.
Should my children be tested for hereditary elliptocytosis?
Because the condition follows autosomal dominant inheritance, each of your children has a 50% chance of inheriting it. Testing may be considered if there are symptoms or for family planning purposes. A genetic counsellor can discuss the benefits and limitations of testing for your family's specific circumstances.
Does hereditary elliptocytosis affect life expectancy?
People with typical hereditary elliptocytosis have a normal life expectancy. The condition does not progress to more serious blood disorders, and most affected individuals live entirely normal lives without medical complications.
References
- Jha SK, Vaqar S. Hereditary Elliptocytosis. 2024. PMID: 32966004
- Narla J, Mohandas N. Red cell membrane disorders. International journal of laboratory hematology. 2017. PMID: 28447420
- Soderquist C, Bagg A. Hereditary elliptocytosis. Blood. 2013. PMID: 23729040
- Palek J. Hereditary elliptocytosis and related disorders. Clinics in haematology. 1985. PMID: 3886240
- Gallagher PG. Hereditary elliptocytosis: spectrin and protein 4.1R. Seminars in hematology. 2004. PMID: 15071791
- Da Costa L, Galimand J, Fenneteau O. Hereditary spherocytosis, elliptocytosis, and other red cell membrane disorders. Blood reviews. 2013. PMID: 23664421
- Gallagher PG. Abnormalities of the erythrocyte membrane. Pediatric clinics of North America. 2013. PMID: 24237975
- Jia R, Li D, Li M. Spectrin-based membrane skeleton supports ciliogenesis. PLoS biology. 2019. PMID: 31299042